FDA Extends Nexplanon Use
US study data showed zero pregnancies in years 4 and 5 of etonogestrel implant use.
By
Kathryn Wighton
January 20, 2026
Objective: To extend the labeled duration of use of the etonogestrel implant (Nexplanon) for pregnancy prevention from three years to up to five years.
Approach: Key Findings: Nexplanon is effective for up to five years with no pregnancies reported during years 4 and 5. No new safety findings were observed during the extended use. Changes in menstrual bleeding patterns were the most common adverse reaction leading to discontinuation. Interpretation: The updated label for Nexplanon reflects its efficacy and safety for a broader range of women, including those with higher BMIs.
Limitations: The study was open-label and single-arm, which may introduce bias. The long-term effects beyond five years are not evaluated. Conclusion: Nexplanon is now approved for pregnancy prevention for up to five years, enhancing contraceptive options for women.
Sources: